164 related articles for article (PubMed ID: 16781904)
1. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T
Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904
[TBL] [Abstract][Full Text] [Related]
2. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Fujii N; Hamano T; Mikami S; Nagasawa Y; Isaka Y; Moriyama T; Horio M; Imai E; Hori M; Ito T
Nephrol Dial Transplant; 2007 Jun; 22(6):1601-7. PubMed ID: 17124283
[TBL] [Abstract][Full Text] [Related]
3. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
5. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
6. A new approach for evaluating bone turnover in chronic kidney disease.
Tolouian R; Hernandez GT; Chiang WY; Gupta A
Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of bone resorption markers in hemodialysis patients.
Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y
Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165
[TBL] [Abstract][Full Text] [Related]
8. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.
Rosen HN; Moses AC; Garber J; Iloputaife ID; Ross DS; Lee SL; Greenspan SL
Calcif Tissue Int; 2000 Feb; 66(2):100-3. PubMed ID: 10652955
[TBL] [Abstract][Full Text] [Related]
9. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
11. Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
Abe Y; Ishikawa H; Fukao A
Tohoku J Exp Med; 2008 Jan; 214(1):51-9. PubMed ID: 18212487
[TBL] [Abstract][Full Text] [Related]
12. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
13. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
14. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
Garnero P; Aronstein WS; Cohen SB; Conaghan PG; Cline GA; Christiansen C; Beary JF; Meyer JM; Bingham CO
Osteoarthritis Cartilage; 2008 Jun; 16(6):660-6. PubMed ID: 17993283
[TBL] [Abstract][Full Text] [Related]
15. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
17. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
Raisz L; Smith JA; Trahiotis M; Fall P; Shoukri K; Digennaro J; Sacco-Gibson N
Osteoporos Int; 2000; 11(7):615-20. PubMed ID: 11069196
[TBL] [Abstract][Full Text] [Related]
18. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
Baxter I; Rogers A; Eastell R; Peel N
Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
[TBL] [Abstract][Full Text] [Related]
20. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
